Acquired hemophilia a successfully treated with rituximab

Giovanni D'Arena, Elvira Grandone, Matteo Nicola Dario di Minno, Pellegrino Musto, Giovanni D. di Minno

Research output: Contribution to journalArticle

Abstract

Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standard treatments. Here we describe a case of idiopathic AHA in a 60-year old man successfully treated with rituximab. He showed a complete clinical response with a normalization of clotting parameters after 5 weekly courses of rituximab given at a dose of 375 mg/sqm., but after stopping rituximab, an initial worsening of coagulation parameters induced the addition of 3 further courses. At present, the patient is in complete clinical and hematological remission after 200 days. This case confirms that Rituximab may be a safe and useful tool to treat AHA and, a prolonged administration can overcome the initial resistance. However, the precise position of this drug in the therapeutic strategy (first or second-line, alone or in combination with other drugs) remains to be established and warrants further investigation.

Original languageEnglish
Article numbere2015024
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume7
Issue number1
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Acquired hemophilia a successfully treated with rituximab'. Together they form a unique fingerprint.

  • Cite this